CAR-T & Cell Therapy
CAR-T toxicity is a clock, not a checklist — CRS and neurotoxicity unfold in hours.
See the modality page → Named specialistAntibody-Drug Conjugates
ADCs are not chemotherapy — their organ-specific toxicity demands targeted, organ-aware monitoring.
See the modality page → Named specialistRadioligand Therapy
A dosimetry-safety gap conventional PV isn't trained to see — marrow reserve, renal function, cumulative dose.
See the modality page → Named specialistOncolytic Viruses
Viral shedding, injection-site reactions, and disseminated-infection risk call for a live-biological-agent safety protocol.
See the modality page → Named specialistVaccines
Population-scale safety surveillance and reactogenicity monitoring at a volume most PV systems aren't sized for.
See the modality page →Bispecifics
A cytokine-release profile distinct from CAR-T — step-up dosing and early-cycle monitoring built around that difference.
Talk to a specialist →Gene Therapy
Long-term follow-up design — often 15 years — with integration and immunogenicity risk that outlasts the trial itself.
Talk to a specialist →CNS
Blood-brain-barrier delivery and subjective endpoints demand a different bar for signal definition and adjudication.
Talk to a specialist →Rare Disease
Small, heterogeneous populations where every safety signal carries outsized statistical and clinical weight.
Talk to a specialist →Named specialist pages are added as our physicians publish clinical depth in a given modality — the network coverage exists today either way.
Talk to a modality expert.
Bring us the toxicity profile, the safety question, or the protocol you're designing — we'll tell you who's the right fit.
Book a call